Invitation - Presentation of Sobi's second quarter 2015

On 16 July, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the second quarter 2015.

Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day at 14:00 CET. The event will be hosted by Sobi's CEO and President, Geoffrey McDonough, and the presentation will be held in English.

The presentation can be followed live, or afterwards on www.sobi.com. Slides used in the presentation will be made available on our website prior to the telephone conference.

To participate in the telephone conference, please call:
SE: [phone]
UK: [phone]
US: [phone] 

Live audience URL: http://event.onlineseminarsolutions.com/r.htm?e=1011451&s=1&k=BB14F0C1 ...   (The recording will be made available via the audience URL within three hours after the live broadcast using the same link.)

---

About Sobi

Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.

 

For more information please contact

Media relations	Investor relations
Oskar Bosson, Head of Communications	Jörgen Winroth, Vice President, Head of Investor Relations
T: [phone]	T: [phone], [phone], [phone]
[e-mail]	[e-mail]

023e_Earnings call invitation Q2 2015

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire

HUG#1931658